The efficacy of a new photosensitizer of chlorin E6 conjugated with a prostate-specific membrane antigen (PSMA) in photodynamic therapy of murine melanoma B16 was studied in in vivo experiments. The dynamics of photosensitizer accumulation in the tumor and surrounding tissues was evaluated and antitumor efficacy of photodynamic therapy was assessed by parameters of regression and morphological characteristics of experimental transplanted melanoma B16. The inhibitory effect of photodynamic therapy on melanoma was evaluated by complete regression of the tumor, absolute tumor growth coefficient in animals with continuation of tumor growth, and the increase in life span in comparison with the control; the criterion of cure was the absence of signs of tumor recurrence in mice within 90 days after therapy. The therapeutic potential of photodynamic therapy was determined by devitalization of tumor cells (histological examination of the zones of laser exposure on day 21 after treatment). The photosensitizer with PSMA-ligand exhibited high antitumor activity in photodynamic therapy for melanoma B16. Photodynamic therapy carried out at the optimum time after photosensitizer injection with experimentally determined parameters of laser exposure allows achieving the maximum inhibitory effect on melanoma. Pathomorphological study in the zones of exposure detected no survived tumor cells.
Similar content being viewed by others
References
Burmistrova NV, Drozhzhina VV, Kaplan MA, Yuzhakov VV, Bandurko LN, Tsyganova MG, Ivanov SA, Arkhipova LM, Abramova OB. Study of efficiency of photodynamic therapy of Earlich carcinoma mice with intravenous introduction of photosensibilizer of liposomal boronated chlorine E6. Radiats. Risk. 2019;28(4):96-107. doi: https://doi.org/10.21870/0131-3878-2019-28-4-96-107. Russian.
Grin MA, Suvorov NV, Machulkin AE, Plotnikova EA, Yakubovskaya RI, Mazhuga AG, Mironov AF, Filonenko EV. Patent RU No. 2670087. Photosensitizer for photodynamic therapy of prostate cancer and method for manufacturing thereof. Bull. No. 29. Published October 18, 2018.
Bařinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr. Med. Chem. 2012;19(6):856-870. doi: https://doi.org/10.2174/092986712799034888
Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl Acad. Sci. USA. 2005;102(17):5981-5986. doi: https://doi.org/10.1073/pnas.0502101102
Nimmagadda S, Pullambhatla M, Chen Y, Parsana P, Lisok A, Chatterjee S, Mease R, Rowe SP, Lupold S, Pienta KJ, Pomper MG. Low-level endogenous PSMA expression in nonprostatic tumor xenografts is sufficient for in vivo tumor targeting and imaging. J. Nucl. Med. 2018;59(3):486-493. doi: https://doi.org/10.2967/jnumed.117.191221
Pavlícek J, Ptácek J, Barinka C. Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme. Curr. Med. Chem. 2012;19(9):1300-1309. doi: https://doi.org/10.2174/092986712799462667
Suvorov NV, Ivanova AV, Popkov AM, Bondareva EA, Mironov AF, Grin MA, Majouga AG, Machulkin AE, Plotnikova EA, Yakubovskaya RI. Synthesis of PSMA-targeted 131- and 152-substituted chlorin E6 derivatives and their biological properties. J. Porphyrins Phthalocyanines. 2018;22(11):1030-1038. doi: https://doi.org/10.1142/S1088424618501006
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostatespecific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637-640. doi: https://doi.org/10.1016/s0090-4295(98)00278-7
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 171, No. 4, pp. 481-485, April, 2021
Rights and permissions
About this article
Cite this article
Abramova, O.B., Kaplan, M.A., Grin, M.A. et al. Photodynamic Therapy of Melanoma B16 with Chlorin E6 Conjugated with a PSMA-Ligand. Bull Exp Biol Med 171, 468–471 (2021). https://doi.org/10.1007/s10517-021-05252-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-021-05252-x